Abstract
Background: Brugada Syndrome (BrS) is an inherited arrhythmia disorder that causes an elevated risk of sudden cardiac death. Approximately 20% of patients with BrS have rare variants in SCN5A, which encodes the cardiac sodium channel NaV1.5. Genetic workup of BrS is often complicated by SCN5A variants of uncertain significance (VUS) and/or incomplete penetrance. Methods: We analyzed all 252 missense and in-frame insertion/deletion SCN5A variants from a previously published large cohort of BrS cases (n=3,335 patients) using a calibrated high-throughput automated patch clamp (APC) assay. Variant functional Z-scores were assigned evidence levels ranging from BS3_moderate (normal function) to PS3_strong (loss-of-function), as defined by American College of Medical Genetics and Genomics criteria. Functional evidence was combined with population frequency, hot-spot, case counts, protein length changes, and in silico predictions. Odds ratios of BrS case-control enrichment and penetrance for BrS were calculated from variant frequencies in the BrS cohort and in gnomAD. Results: Most variants (146/252) were functionally abnormal (Z ≤ −2), with 100 having severe loss-of-function (Z ≤ −4). Functional evidence enabled the reclassification of 110 of 225 VUS; 104 to likely pathogenic and 6 to likely benign. SCN5A variants with loss-of-function were mainly localized to the transmembrane domains, especially the regions comprising the central pore. SCN5A variant penetrance was proportional to the severity of loss-of-function; variants with Z ≤ −6 had penetrance of 24.5% (15.9 − 37.7% CI) and an odds ratio of 501 for BrS. Conclusions: This cohort-scale APC dataset stratifies SCN5A variants found in BrS patients into normal function ″bystander″ variants that have a low risk for BrS and loss-of-function variants that have a high risk for BrS. Functional data can be integrated with other criteria to reclassify a substantial fraction of VUS. The dataset helps clarify the SCN5A-BrS relationship and will improve the diagnosis and clinical management of BrS probands and their families.
Competing Interest Statement
Dr. Glazer is a consultant for BioMarin, Inc.
Funding Statement
This study was funded by the National Institutes of Health (NIH): R00 HG010904 (AMG), R35 GM150465 (AMG), R01 HL164675 (DMR), and R01 HL149826 (DMR), a New South Wales Cardiovascular Disease Senior Scientist grant (JIV), and a Medical Research Future Fund: Genomics Health Futures Mission grant MRF2016760 (JIV and CAN). MJO received support from NIH grants F30HL163923 and T32GM007347. VUMC flow cytometry experiments were performed in the Vanderbilt Flow Cytometry Shared Resource. The Vanderbilt Flow Cytometry Shared Resource is supported by the Vanderbilt Ingram Cancer Center (NIH P30 CA68485) and the Vanderbilt Digestive Disease Research Center (NIH DK058404). The VUMC Nanion SyncroPatch 384PE is housed and managed within the Vanderbilt High-Throughput Screening Core Facility, an institutionally supported core, and was funded by NIH Shared Instrumentation Grant 1S10OD025281. The HTS Core receives support from the Vanderbilt Institute of Chemical Biology and the Vanderbilt Ingram Cancer Center (NIH P30 CA68485). JB and CRB are supported by the European Innovation Council Pathfinder Project Nav1.5-CARED (101115295).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at: Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls, published in GENETICS IN MEDICINE 2021 (pmid: 32893267)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the supplementary tables
